“Tim is a weird-science guy." A 74-year-old professor at Harvard Medical School and a research lab chief at Boston Children’s Hospital is a heads-down scientist and entrepreneur with some notable quirks.
A Cambridge, Mass., biotech company claims to have made a discovery that could rewrite biology textbooks.
Moderna chair Noubar Afeyan launched an unflinching defense of the board’s executive hiring process after it was forced to fire its new chief financial officer last week.
Afeyan founded Flagship in 2000, building it into one of the world’s leading life science venture capital firms — often conceiving or incubating companies itself. Flagship has made numerous successful investments in recent years, among them Rubius Therapeutics, which bioengineers red blood cells to create new cellular therapies. But Flagship’s most notable success is Moderna,…
Though “Moderna” is now used as a shorthand for a Covid-19 vaccine, developing vaccines was not originally in the company's game plan.
A large majority of Americans support allowing the U.S. government to negotiate for Medicare drugs, a Kaiser Family Foundation poll shows.
2021 STAT Summit will feature NIAID Director Dr. Anthony Fauci and Pfizer CEO Albert Bourla BOSTON, MA - Today, STAT, the nation’s must-read health, science, and medicine publication, announced its 2021 STAT Summit. The event will be hybrid from November 16-18, 2021, with programming taking place from 1:00 - 4:30 p.m. ET each day. The…
A Flagship Pioneering fund reported a 15x investment multiple, the highest of any included in a new STAT report that looks at returns for 17 major biotech venture capital firms during the pandemic.
nov 16-18hybrid event#statsummit View Highlights About Charting a course for medicine's future Leading figures in science and medicine joined us at the 2021 STAT Summit. Corporate executives, top scientists, patient advocates, and government officials had spirited discussions with each other, and with STAT’s award-winning reporters. They answered your questions and dove deep into the hottest…
In an interview with STAT, Hahn said no one from Moderna played any part in his transition to Flagship Pioneering, the venture capital firm with close ties to the Covid-19 vaccine maker.
Founders and investors have been allowed to bend the course of the pandemic to their private benefit. When a few people win big, everyone else loses.
Moderna chief executive Stephane Bancel shrugged off the Biden administration’s support for suspending patents for coronavirus vaccines.
Flagship Pioneering, the venture capital firm behind Moderna Therapeutics, has an internal culture to match its exterior image: brazen, unconventional, and incredibly demanding.
The story of mRNA began is a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash in biotech.
Many international students who train in the U.S. want to stay here, rent or buy homes, dine at restaurants, shop at local stores, participate in our economy, become active members of the community, and even pay taxes, all while contributing to scientific discoveries with the potential to transform society — or at least they used…
In the name of national security, the world's countries have amassed enough nuclear weapons to destroy human civilization, and they accept the massive financial investment. We need the same aggressive approach for health security.
These are difficult times. But two of the top biotech venture firms just raised a total of $2.6 billion to fund new startups.
“With Ring, we are truly forging new ground by pioneering an entirely new category of DNA medicines based on nature,” said Noubar Afeyan, founder and chief executive of Flagship.
Here are @adamfeuerstein's nominees for worst biopharma CEO of 2019.
Sana Biotechnology's early code name, FD Therapeutics, hints at the buzzy startup's aggressive vision. Guess what it stands for.
One of Flagship Pioneering’s single-cell sequencing startups is inching out of stealth mode.
In biotech, funding doesn’t just fall into scientists’ and entrepreneurs’ laps. @sheridan_kate explains how venture capital works.
Since 2000, Flagship has raised a total of $3.3 billion to spawn and finance biotech, medical technology, and bio-agriculture businesses.
A University of Guelph scientist uses a mechanical colon she calls the "Robogut" to study the gut microbiome and produce "feces" for a clinical trial to treat C. difficile infections.
The new venture round — Flagship’s largest one-time infusion ever — boosts to $2.3 billion the total capital raised by the firm since its founding in 2000.
Moderna Therapeutics, a $5 billion startup that boasts of changing the world, is losing a key partner, imperiling its most advanced drug project.
Venture capital firms are branding themselves with ever snazzier, snappier, more ahead-of-the-curve names. Our question: Why bother?
Moderna's caustic work environment has driven away top talent. There are signs the secretive startup has hit roadblocks with its most ambitious projects.
Katrine Bosley has the biotech chops to help make medicines out of CRISPR gene-editing technology.
